Michael A. B. Naafs, PhD

Dutch Internist-Endocrinologist

Health Consultant at Naafs,International Health Consultancy

Rhodoslaan 20, 7577KN, Oldenzaal, Netherlands


Biography

Michael A.B. Naafs is a Dutch internist-endocrinologist with a long clinical career in internal medicine and endocrinology .
His PhD Endocrinology was obtained at Leiden University (1988) and focused on the renal end-organ resistance to PTH (Parathormone) infusion in normo-and hypercalcaemic patients with solid tumors secreting a PTH-like factor.
Other area’s of interest are clinical pharmacology where he was in the front of clinical research of transdermal nitroglycerin patches.(1984) Recently he participated in the standard book project “Drug Discovery and Evaluation: Methods in Clinical Pharmacolgy “Eds Hock.F.J,Gralinski M.R 2nd Edition, 2017, Springer Verlag, providing the section “Pharmacodynamic Evaluation: Endocrinology “.
In infectious medicine he was one of the first to report about HIV-2 infection (1990) Experience in HIV,MDRTB and tropical Infectious medicine was acquired during a one year stay at Nelson Mandela Academic Hospital,Umthata,South Africa.( 2008).
At present he works as an independent health consultant (Naafs International Health Consultancy ) and as a Medical Writer. Michael is an editorial board member of a number open access journals and the author of tenfolds of publications.

Research Interest

Scientific Activities

Publications

1. The urinary excretion of camp in patients with malignant tumors. P.C. van der Velden, M.A.B. Naafs, H.R.A. Fischer, W.H.L. Hackeng, G. Koorevaar, W. Schopman, J. Silberbusch. Neth. J. Med. 1983; 26: 10-17.
2. Renal clearance of digoxin in man after sodium loading or furosemide treatment. M.A.B. Naafs, C. van der Hoek, W. Schopman, S. van Duin, G. Koorevaar, J. Silberbusch. Eur. J. Clin. Pharmacol. 1983; 25: 375-379.
3. Histamine en parathyroid activity. P.C. van der Velden, M.A.B. Naafs, J.H. Paulusma & de Waal, J. Silberbusch. Horm. Metab. Res. 1984; 16: 269-270.1.
4. Changes in nephrogenous cyclic AMP excretion and plasma cyclic AMP following treatment of hyperthyroidism. M.A.B. Naafs, P.C. van der Velden, H.R.A. Fischer, G. Koorevaar, S. van Duin, W.H.L. Hackeng, W. Schopman, J. Silberbusch. Acta Endocrinol. (Copenh.) 1984; 106: 477-481.
5. Exercise capacity with transdermal nitroglycerin in patients with stable angina pectoris. M.A.B. Naafs, A.C. de Boer, R.W. Koster, C.W. Klazen, A.J. Dunning. Eur. Heart J. 1984; 5: 705-709.
6. Acutesuppuratievethyreoiditis. M.A.B. Naafs, H.R.A. Fischer, E.E.J. Ligtvoet, J. Silberbusch. Ned. Tijdschr. Geneeskd. 1985; 1292-1293.
7. Decreased renal clearance of digoxin in chronic congestive heart failure. M.A.B. Naafs, C. van der Hoek, S. van Duin, G. Koorevaar, W. Schopman, J. Silberbusch. Eur. I. Clin. Pharmacol. 1985; 29: 249-252.
8. Influence of pharmacological doses of calcitonin on serum B2 microglobulin concentration. H. Mulder, H. van Bolhuis, M.A.B. Naafs, P.L.M. Winckers. Calcif. Tissue Int. 1985; 37: 367-371.
9. End-organ resistance to PTH-infusion in hypercalcaemic and normocalcaemicpatiente with solid tumours. M.A.B. Naafs, H.R.A. Fischer, P.C. van der Velden, H. Mulder W.H.L. Hackeng, W. Schopman, G. Koorevaar, J. Silberbusch. Acta Endocrinol. (Copenh.) 1986; 113: 543-550.
10. Een nonogram voor dosisbepaling van digoxine voor bejaarde patienten met boezemfibrileren. M.A.B. Naafs, J. Silberbusch. Ned. Tijdschr. Geneeskd. 1987; 507.
11. Once a week high dose thyroid hormone replacement therapy in a hypothyroid patient. M.A.B. Naafs, H.R.A.Fischer, P.P.M. Bender: J. Silberbusch. Neth. J. Med. 1987; 30: 187-192.
12. Changes in serum osteocalcin following treatment of mild hyperthyroidism. M.A.B. Naafs, A.C. de Boer, H.R.A. Fischer, W.H.L. Hackeng, Silberbusch. Neth. I. Med. 1987; 31: 52-57.
13. The effect of age on the renal response to PTHinfusion. M.A.B. Naafs, H.R.A. Fischer: G. Koorevaar, W.H.L. Hackeng, W. Schopman, J. Silberbusch. Calcif. Tissue Int. 1987; 41: 262-266.
14. Abnormal responsiveness of nephrogenous cyclic AMPexcretion following intravenously administered calcium in normocalcaemic squamous cell cancer patients. M.A.B. Naafs, W.H.L. Hackeng, G. Koorevaar, J. Silberbusch. Bone and Mineral 1988; 4: 289-298.
15. Predicted and actual clinical potency of a new third generation bisphosphonate. O.L.M. Bijvoet, K. Hoekman, M.A.B. Naafs, S.E. Papapoulos. J. Bone Min. Res. 1988; 3: S 129.
16. De invloed van veranderingen in de concentratie van het serum parathyreoid hormoon op de responspatronen van de nier. 1. M.A.B. Naafs Academisch proefschrift. Leiden, 7 december 1988.
17. Acute pancreatitis in a case of Werner’s syndrone with severe hyperlipidaemia. M.A.B. Naafs, H. Schouwink, G.G. Roeleveld, E.H. Slaats, J. Silberbusch. Neth. J. Med. 1989; 34:4: 194-200.
18. The influence of transdermal estradiol on PTH-release in postmenopausal women with primary hyperparthyroidism. W.M. Smit, M. Louwers, E.H. Slaats, M.A.B. Naafs, J. Silberbusch. Calcif. Tissue Int. 1989; 44: S 26.
19. De pathogenese van het humorale hypercalciemie syndroom bij patienten met een solide tumor. M.A.B. Naafs, J. Silberbusch. Ned. Tijdschr. Geneeskd. 1989; 21: 1065-1069.
20. Aggravation of hypoglycaemia in insulinoma-patients by the longacting somatostatin analogue Sandostatin. C.D.A. Stehouwer, W.F. Lems, H.R.A. Fischer, W.H.L. Hackeng, M.A.B. Naafs. Acta Endocrinol. (Copenh.) 1989; 121: 34-40.
21. The influence of transdermal estradiol on PTH-release in postmenopausal women with primary hyperparathyroidism and in osteoporosis. W.M. Smit, E.H. Slaats, M.A.B. Naafs, C.L. van Schaik, I. Silberbusch. J. Bone Min. Res. 1989; 4: s: 172.
22. The usefulness of an oral calcium tolerance test in the management of patients with idiopathic hypercalciuria. M.A.B. Naafs, E. Essed, W.H. Hirdes, W.H.L. Hackeng, H.R.A. Fischer. Neth. J. Med. 1990; 36: 223-227.
23. HIV-2 Infectie bij een in Nederland wonende Portugese vrouw met een AIDS dementiecomplex. J. Nouwen, J. Buitenwerf, A.M. Boelmans-Kranenburg, H. Geldof, M.A.B. Naafs. Ned. Tijdschr. Geneeskd.. 1990; 134:1: 26-28.
24. Pijn in een arthrotische heup; niet altijd ‘oud nieuws’. J.W. Manten, A.J.W. Marsman, H.L.M. Brus, M.A.B. Naafs. Ned. Tijdschr. Geneeskd. 1994; 49: 2425-2427.
25. CIOP in adolescents treated for pulmonary disease. M.A.B. Naafs, Poster presentation 25th European Symposium on Calcified Tissues Harrogate UK 1997
26. Snelle fractuurbescherming van risedronaat nu ook beschikbaar in wekelijkse dosering . M.A.B. Naafs. Modern Medicine 2003; 3; 233-34
27. Het antifractuureffect van risedronaat is groter dan dat van nasal calcitonine en alendronaat. M.A.B. Naafs. Modern Medicine 2003; 9; 680-81
28. Michael AB Naafs.,2017, Pharmacodynamic Evaluation: Endocrinology,Chapter 35; doi: 10.1007/978-3-319-56637-5_35-1.
29. Drug Discovery and Evaluation: Methods in Clinical Pharmacology, 2nd Edition, Editors Hock F.J, Gralinski M.R. Springer Verlag Berlin ,Heidelberg,New York.
30. Michael AB Naafs,2017, Clinical Pharmacodynamics of Endocrine Disruptors:A Historic Perspective. Endocrinol.Diabetes Res. 2017;4;(1);1000128.
31. Michael AB Naafs, 2018. Antimicrobial Properties of Copper and Copper Alloys in Infection Control. InfectionControl.tips; 2017;Aug 9; www.IC.tips .
32. Michael AB Naafs, 2017. Pheromones: Honey’s and Queens. Glob.J.Otolaryngol.,2017;9;(5);555775;DOI 10 19080/GJO 2017,09.555 775.
33. Michael AB Naafs,2017. The Maggots: Professional Wound Cleaners. InfectionControl.tips: 2017; Oct 31, www.IC.tips.
34. Michael AB.Naafs,2017. The Antimicrobial Peptides : Ready for Clinical Trials ? Biomed.J.Sci.&Tech.Res ,BJSTR,2018;MS.ID.001596;doi:1026717/BJSTR.2018.07.001536.
35. Michael AB Naafs,2017. Second Messengers in Endocrinology: A Mini-Review of the Cyclic Nucleotides. Endocrinol. Metabol. Int. J. 2017; 5(6);00144.DOI:10.15406/emij.2017.05.0144.
36. Michael AB Naafs, 2017. Hypocalcemia in the Critically Ill: A Mini –Review. Endocrinol.Metab.Int.J. 2017;5(4);00130;DOI:10.15406/emij.2017.05.00130.
37. Michael AB Naafs, 2017. Aspiration and Swallowing in Parkinson’s Disease:Two Hundred Years Later. Glob.J.Otolaryngol.. 2017;10(3);555789;DOI 10.19080/GJO 17.10.555789.
38. Michael AB Naafs,2017. Parathyroid Hormone-Related Peptide (PTHrP); A Mini-Review. Endocrinol.Metab.Int.J. 2017;5(6);00139; DOI:10.15406/emij 2017.05.00139.
39. Michael AB Naafs, 2017. Cavernous Sinus Thrombosis in ENT Practice. Glob.J.Otolaryngol. 2017.:10(5);GJO.MS.ID 555798;DOI:10.19080/GJO.2017.10.5
40. Michael AB Naafs,2017, MinimallyInvasive Parathyroidectomy in Primary Hyperparathyroidism: A Mini-Review.
41. Glob.J. Otolaryngol.. 2017;12(2);555831.DOI:10.19080/GJO.2017.12.555831.
42. Michael AB Naafs,2017, Measurement of the Anti-Müllerian Hormone in Clinical Endocrinology: A Mini-Review.
43. Invest.Gynecol.Res.&Women’s Health 2017;1(2);IGRWH 00509.
44. Michael AB Naafs,2017. Lugol’s Solution in Thyroid Surgery: A Mini-Review. Glob.J.Otolaryngol. 2017;11(4);555817;Doi 10-19080/GJO 2017.11555817.
45. Michael AB Naafs,2018. Calcitonin-Gene Related Peptide (CGRP) in Pain and Migraine: A Mini-Review. Endocrinol. Metab.Int.J. 2018;6(2);130-135;Doi:10.15406/emij.2018.06.00166.
46. Michael AB Naafs,2018. Labyrinthitis Vestibular Neuritis, And Sensorineural Hearing Loss(SNHL).,2018. Glob.J.Otolaryngol. 2018,Doi:10.19080/GJO.2018.15.555914.
47. Michael AB Naafs,2018. The Fetal Alcohol Spectrum Disorders. Int Gyn.& Women’s Health.,2018;1(2);IGWHC MS.ID.000109.
48. Michael AB Naafs 2018. The Burden of Allergic Rhinitis: A Mini-Review. Glob.J.Otolaryngol. 2018;13(1);555854;DOI:10.19080/GJO.2018.13555854.
49. Michael AB Naafs,2018. Child Abuse and Addiction in Obesity. Invest.Gynecol Res.& Women’s Health 2018;2(2);IGRWH 000534.2018;DOI:10.31031/GRWH.2018.02.000534.
50. Michael AB Naafs,2018. Selective Androgen Receptor Modulators (SARMs): A Mini-Review. Open Acc/Repro &Sexual Disord:1(1)-2018 OAJRSD.MS ID.000103
51. Michael AB Naafs,2018. Microbial Endocrinologyin Microbiology: A Mini-Review. Int.J. Clin.Endocrinol. 2018;2(1);004-010.
52. Michael AB Naafs,2018. Glucocorticoid Chronotherapy: A Mini-Review. Endocrinol.Metab. Int. J. 2018; 6(2);118-122;Doi:10.15406/emij.2018.06.00164.
53. Michael AB Naafs, 2018. Oral Mucosal Immune Suppression,Tolerance and Silencing: A Mini-Review. Mod.App.Dent.OralHealth&Care 2018;1(2);MADOHC;MS.ID.000.109.
54. Michael AB Naafs,2018. The Global Impact of the Mo-99 Shortage Biomed. J.Sci.&Tech. Res. 2018;4(5);MS.ID 0001114;Doi:10.26717/BJSTR 2018.04001114.
55. Michael AB Naafs,2018- Ultra-Processed Foods,GutHealth,Autoimmunity and Diets. CPQ Medicine,2018;2(2);01-12.
56. Michael AB Naafs,2018. The Vasopressin V2 Receptor Antagonists: The Vaptans. Glob. J. Endocrinol. Metab. 2018;2(1);GJEM.000529.2018.
57. Michael AB Naafs,2018. Human Growth Hormone Therapy Int.J.Clin.Endocrinol. 2018;2(1);011-018.
58. Michael AB Naafs,2018. Some of World’s Largest Legionella and Q Fever Outbreaks in a Small Country:Co-Incidence? CPQ Medicine 2018;2(4);01-03.
59. Michael AB Naafs,2018. MetabolicLiver Inflammation in Obesity. CPQ Medicine 2018;1(2);01-17.
60. Michael AB Naafs,2018. Tongue Tie and Breastfeeding: Of the Gap or Another Hype? Mod.App.Dent. Oral Health&Care,2018; 2(4);MADOHC.M.ID.000.142.
61. Michael AB Naafs,2018. Occupational Diseases in the Petrochemical Sector and Offshore Upstream Petroleum Industry. Progress Petrochem. Sci. 2018;2(2);PPS.000.535.2018
62. Michael AB Naafs,2018. Dental DNA Fingerprinting. Mod.App.Dent. Oral Health&Care 2018;2(4);MADOHC.MS.ID.000.143.
63. Michael AB Naafs,2018. Congenital Syphillis: On the Rise Again. Gynaecology&Perinatology (GYPE),2018;2(3);273-80.
64. Michael AB Naafs,2018. Errors in the Total Testing Process (TTP) of Microbiological Samples. CPQ Medicine 2018;1(6);01-07.
65. Michael AB Naafs,2018. Exposomics and Growth Rings in the Teeth. Mod.App.Dent. Oral Health&Care 2018;2(4;MADOHC.MS.ID.000.145
66. Michael AB Naafs, 2018. Persistent Wound Leakage After Total Knee and Hip Arthroplasty. Orthop.&Spo. Med. Op. Acc. J.2018;1(4);2018,OSMOAJ;MS.ID.000116.
67. Michael AB Naafs, 2018. Sensor Technology Developments in Diabetes Monitoring. CPQ Medicine 2018:2(1);01-14
68. Michael AB Naafs,2018. New Insights intoInflammation in Atherosclerosis. Glob.J.Endocrinol.Metab. 2018; 2(4);GJEM.000547.2018;Doi:10.31031/GJEM.2018.02.000547.
69. Michael AB Naafs,2018. Minimal Effect But No Cure For Alzheimer’s with Antidiabetic Drugs. Clin.J.Dia.Care&Control,2018;1(2);18006.
70. Michael AB Naafs, 2018. Is Tauism Dead? Degener.Intell.Develop. Disabilities.,DIDD, 2018:1(4);1
71. Michael AB Naafs,2018. Nutrition and Hearing Loss. Glob.J. Otolaryngol., 2018;18(5);GJO;Ms.ID 555948
72. Michael AB Naafs, 2018. Fitness and Sports After Total Joint Arthroplasty. Journal of Physical Fitness,Medicine and Treatment in Sports (JPFMTS).2018;4(5);JPFMTS;MS.ID 555650
73. Michael AB Naafs,2018. Women’s All Causes Death and Alzheimer’s Disease: An Editorial. CPQ Medicine 2018;2)4);01-04.
74. Michael AB Naafs,2018. Fungal Infections in Gastroenterology. Curr.Tr..Gastr.&Hepatol. 2018;1(3);CTGH;MS.ID.000114.
75. Michael AB Naafs,2018. Shockwave Therapy in Atherosclerosis. LOJ.Med.Sci.2018;1(2);LOJMS.MS.ID.000106.
76. Michael AB Naafs,2018. Is Online Transgender Healthcare The Future? Open Access Repro. & Sexual Disorders 2018:1(4); OAJRSD:MS.ID.000116
77. Michael AB Naafs,2018. FDA Approvals of Medical Devices Under the De Novo Automatic Class 3 Regulations.
78. Biomed.JSci.&Tech.Res. 2018;BJSTR.MS.ID.001623;DOI:10.26717/BJSTR 2018.08.001623.
79. Michael AB Naafs,2018. Lipedema:Therapy Evaluation and Insurance. CPQ Medicine 2018;2(6);01-08.
80. Michael AB Naafs, 2018. Herd Immunity:A Realistic Target?Biomed.J.Sci&Tech.Res.2018;9(2);BJSTR.MSID.001779;Doi:10.26717/BJSTR.2018.09.001779.
81. Michael AB Naafs,2018. Hurricanes,Floods and Ritual Infectious Disease Outbreak Warnings. CPQ Medicine,2018,:3(1);01-11
82. Michael AB Naafs,2018. Vascular Complications of Parapharyngeal Abscesses. Onlne Journal of Otorlaryngology and Rhinology2018,in press.
83. Michael AB Naafs,2018. Klinefelter Syndrome and Fertility Preservation. Reproduction&Sexual Disorders International Journal 2018,in press
84. Michael AB Naafs, 2018. The Effect of Fitness,Sports,and Lifestyle Factors on All Causes Mortality and Insurance Premiums. Journal of Sports,Science and Physical Therapy. 2018,JSSPT;102.
85. Michael AB Naafs,2018. New developments for Gout. CPQ Medicine,submitted for publication.
86. Michael AB Naafs, 2018. Developments for the Greater Trochanteric Pain Syndrome (GTPS). J.Sports.Sci.PhysicalTher.;submitted for publication.
87. Michael AB Naafs,2018. NovelHyperkalemia Drugs. CPQ Medicine,2018,submitted for publication.
88. Michael AB Naafs,2018. Thrombocytopenia in Chronic Liver Disease: New Developments. Curr.Tr.Gastr. &Hepatol. 2018; submitted for publication
89. Michael AB Naafs,2018. Curcumin and Food Nanotechnology. CPQ Medicne,2018,submitted for publication.
90. Michael AB Naafs,2018. Medical Benefits of Coffee and Tea. EBook,JuniperPublishers,in preparation.

Join as a Editor